CRISPR Therapeutics AG
COMPOSITIONS AND METHODS FOR GENE EDITING

Last updated:

Abstract:

The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL3 gene in a cell by genome editing.

Status:
Application
Type:

Utility

Filling date:

21 Feb 2018

Issue date:

21 May 2020